NasdaqGS:ONCBiotechs
Assessing BeOne Medicines (ONC) Valuation After FDA Accelerated Approval For BEQALZI
The latest move in BeOne Medicines (NasdaqGS:ONC) has been shaped by the U.S. FDA granting accelerated approval to BEQALZI, or sonrotoclax, for adults with relapsed or refractory mantle cell lymphoma after at least two prior therapies.
See our latest analysis for BeOne Medicines.
Recent approvals and clinical partnerships have come alongside a 7 day share price return of 5.79%, while the 90 day share price return is down 14.33% and the 1 year total shareholder return is 28.51%. This suggests...